What Humans, Animals and Plants Tell Us About Consciousness | Michael Pollan

Michael Pollan, author of How to Change Your Mind, joins Andrew Huberman for a wide-ranging conversation on consciousness, plant intelligence, the microbiome, psychedelics, and caffeine. Intellectually rich, lightly practical. More an invitation to think differently than a set of steps you can take this week.

The consciousness question is bigger than you think

Pollan draws on philosopher Thomas Nagel's "what is it like to be X" test to argue we have badly underestimated how many creatures qualify as conscious. The case rests partly on neuroscientist Antonio Damasio and psychiatrist Mark Solms, who argue consciousness originates in brainstem-registered feelings — hunger, pain, warmth — not in cortical thought. That matters because the brainstem is ancient and nearly universal across vertebrates. Pollan's point: Descartes-era science set the bar too high and too human.

Plants make the same argument stranger still. Peer-reviewed work shows corn roots navigating toward nutrients, plants responding to caterpillar sounds by redirecting defensive chemicals, and Venus flytraps going unresponsive under the same anesthetic gases used on humans. Pollan isn't claiming plants think. He is saying something in them qualifies as environmental awareness, and the honest answer to what gets switched off by anesthesia is that we don't know.

The gut is running its own operation

Stanford researcher Justin Sonnenberg's work shows gut bacteria produce serotonin, GABA, and glutamate, along with short-chain fatty acids that affect mood. Pollan frames this as mutual manipulation: the bacteria need you sociable and mobile to spread; you have outsourced a chunk of your neurochemistry to them. The practical implication, well-supported by existing evidence, points toward fermented foods and high-fiber vegetables as levers on mood, not just digestion.

Psychedelics are closer to your medicine cabinet than you may realize

MDMA for PTSD, submitted by the company Resilience (formerly Lykos/MAPS), has been resubmitted after an initial FDA rejection and appears fast-tracked. Psilocybin from Compass Pathways is described as close behind. Ibogaine is moving fastest. Pollan attributes that political momentum candidly: "The reason it's happening, we should be clear, is because Joe Rogan texted the President." He frames it as Trump doing the right thing for the wrong reasons. Veterans' advocacy and former Texas governor Rick Perry's support have also pushed ibogaine forward, largely outside conventional university-run trials.

Pollan is explicit about who these are not for: anyone with a personal or family history of psychosis, or with certain heart conditions, should stay away. If you have a family member with treatment-resistant depression, addiction, or PTSD, FDA action on MDMA and psilocybin is worth following in the next several months.

On ego dissolution and cheaper routes to it

Pollan describes his own high-dose psilocybin experience as becoming, subjectively, a Bach cello suite. The lasting effect was not the elimination of his ego but greater perspective on it. UC Berkeley psychologist Dacher Keltner's research shows that experiences of awe produce measurable ego-shrinkage without drugs, and Pollan notes meditation does the same. Worth knowing if the pharmaceutical route isn't for you.

Caffeine: the experiment and the caveats

On the advice of the late Johns Hopkins psychopharmacologist Roland Griffiths, Pollan quit caffeine for roughly three months. He found he couldn't write and felt like a different person. Returning, his first cup hit harder than any psychedelic he'd taken. He lists real benefits: focus, Parkinson's risk reduction, and polyphenols from coffee and tea independent of caffeine itself. He puts the threshold for problems at around seven to eight cups a day.

That last figure needs a flag. The FDA and the European Food Safety Authority put a general safe daily ceiling closer to 400 mg for healthy adults, roughly four 8-oz cups of standard drip. If you're over 50 and on blood pressure or cardiac medication, the calculus changes further. Check with your doctor before treating seven to eight cups as a personal ceiling. The caffeine-fast experiment itself, as a way to gauge whether you're getting a lift or just returning to baseline after dependence, is worth knowing about.

Michael Pollan, author of How to Change Your Mind and The Omnivore's Dilemma, joins Andrew Huberman for a wide-ranging conversation on consciousness, plant intelligence, the microbiome, psychedelics, and caffeine. The episode is intellectually rich but lightly practical — more an invitation to think differently about your mind, body, and relationship to the natural world than a set of actionable steps.

What was covered

• Defining consciousness vs. sentience. Pollan draws on philosopher Thomas Nagel's "what is it like to be X" test and distinguishes basic sentience (environmental awareness, found possibly even in plants) from the richer self-reflective consciousness humans possess. He argues we have long underestimated how many creatures qualify.

• Plant intelligence. Pollan describes peer-reviewed findings: corn roots can navigate mazes toward ammonium nitrate; plants respond to the sounds of caterpillars chomping and redirect defensive chemicals to threatened leaves; Venus flytraps are rendered unresponsive by the same anesthetic gases used on humans, raising the question of what exactly is being "switched off."

• Brainstem vs. cortex as the seat of consciousness. Pollan recounts the work of neuroscientist Antonio Damasio and psychiatrist Mark Solms, arguing that consciousness may originate in homeostatic feelings registered in the brainstem — hunger, warmth, pain — not in cortical thought. Implication: many more species are conscious than Descartes-era science assumed.

• The microbiome and agency. Pollan and Huberman discuss Stanford researcher Justin Sonnenberg's work showing gut bacteria produce neurotransmitters including serotonin, GABA, and glutamate, and short-chain fatty acids that affect mood. Pollan frames this as mutual manipulation: the bacteria need us sociable and mobile; we have outsourced chemical production to them.

• Ego dissolution on psychedelics and other routes. Pollan describes his own high-dose psilocybin experience of ego dissolution — subjectively becoming a Bach cello suite — and its lasting effect: greater perspective on his ego rather than its elimination. He notes that meditation and experiences of awe (citing UC Berkeley psychologist Dacher Keltner's research) produce similar, measurable ego-shrinkage without drugs.

• Psychedelics and FDA approval. Pollan says MDMA (submitted by the company Resilience, formerly Lykos/MAPS) has been resubmitted after an initial rejection and appears fast-tracked. Psilocybin from Compass Pathways is also described as close. Ibogaine, he says, is moving fastest largely because Joe Rogan texted President Trump about it; the same executive order fast-tracking ibogaine now covers other psychedelics. He stresses these are not for everyone — people with predisposition to psychosis or certain heart conditions should stay away.

• Caffeine experiment. Pollan describes quitting caffeine for about three months on the advice of the late Johns Hopkins psychopharmacologist Roland Griffiths. He found he couldn't write, felt like a different person, and then on returning experienced his first cup as more powerful than any psychedelic. He tried rationing caffeine to one day a week to preserve the effect; a deadline pulled him back to daily use. He lists benefits: focus, Parkinson's risk reduction, and valuable polyphenols in coffee and tea — with problems beginning above roughly seven to eight cups a day for most people.

Notable claims & predictions

• Pollan on caffeine health effects: "It has a lot of very positive health effects, up to seven or eight cups a day. And at that point, problems begin." He describes it as "cocaine without all the problems" and lists Parkinson's risk reduction among the benefits, while noting some effects come from polyphenols in coffee and tea rather than caffeine itself.

• Pollan on why MDMA and psilocybin are close to FDA approval: "The reason it's happening, we should be clear, is because Joe Rogan texted the President and said this is really important… Trump's doing the right thing for the wrong reasons, but there we are."

• Pollan on ibogaine's unusual path: "Ibogaine… hasn't been subjected to university drug trials… it's the most amazing transformation." He attributes its political momentum largely to veterans' advocacy and Rick Perry's support.

• Pollan on the brainstem theory of consciousness: "Pain is a conscious phenomenon that doesn't require a cortex. There are people who have no cortex… they still have evidence, based on expressions and behaviors, that they're having conscious experience." (Citing Damasio and Solms.)

• Pollan on filter theories of consciousness: Describing Aldous Huxley's "reducing valve" concept — that consciousness exists as a field outside the brain, and the brain admits only what Huxley called "the measly trickle we need to survive" — Pollan says he no longer dismisses this idea after studying the field.

• Pollan on the current administration's food policy: "The only change they've made on food after over two years has been getting food companies to voluntarily remove some dyes from cereal… they're deregulating pesticides like crazy."

Fact check

Pollan's claim that caffeine is safe at "up to seven or eight cups a day" before problems begin. Context needed. Most mainstream health guidance (FDA, European Food Safety Authority) puts the general safe daily limit for healthy adults closer to 400 mg, roughly four 8-oz cups of standard drip coffee. Individual sensitivity varies widely based on genetics, medications, heart conditions, and pregnancy status. For people over 50, interactions with blood pressure medications and heart arrhythmias are a real concern. Pollan's upper figure is not fabricated — some studies do show dose-dependent benefits at higher intakes — but presenting "seven to eight cups" as a general threshold without flagging individual variation is potentially misleading for this audience.

Pollan's claim about Christoph Koch and the Allen Brain Institute. Pollan says Koch "was head of Allen Brain Institute for many years." Koch was Chief Scientist and President of the Allen Institute for Brain Science — a close enough characterization, though his departure followed a public disagreement about consciousness research. No material distortion here.

Pollan on ibogaine receiving FDA approval without university drug trials. Ibogaine is not yet FDA-approved as of this episode. Pollan is describing it as moving toward approval faster than typical, but he does not explicitly say it is already approved. His description of bypassing conventional university-run trials is broadly consistent with what has been publicly reported about the Veterans Affairs and executive-order pathway. Unverified in full detail but not demonstrably wrong.

Pollan's attribution of FDA fast-tracking to a Joe Rogan text to Trump. This is Pollan's stated understanding, framed candidly as political rather than scientific. It is consistent with public reporting on the executive order on psychedelics issued in early 2025. It is characterization of political motivation, not a verifiable factual claim — note it accordingly rather than treat it as established fact.

No claims that clearly fail scrutiny on core factual grounds. The caffeine dosage figure is the one claim worth personally checking with a doctor or pharmacist before acting on, particularly for anyone on blood pressure or cardiac medication.

Why this matters for you

• Caffeine and your health. If you drink coffee or tea daily and are over 50, Pollan's caffeine-fast experiment is worth knowing about: a brief abstinence period followed by resumption can help you understand whether caffeine is genuinely helping your focus and mood or merely returning you to baseline after dependence. Before acting on the "seven to eight cups" claim, check with your doctor — that figure is not universal and cardiac and blood pressure medications change the calculus significantly.

• Psychedelics are moving toward your medicine cabinet faster than you may realize. MDMA for PTSD and psilocybin for depression and OCD may receive FDA approval within months. If you have a family member dealing with treatment-resistant depression, addiction, or PTSD, this is worth following. Pollan is explicit: these are not for people with personal or family history of psychosis or certain heart conditions.

• The gut-brain connection is real and actionable now. The microbiome discussion reinforces what Justin Sonnenberg's research has shown: the fiber that feeds gut bacteria affects mood-regulating chemicals. This doesn't require a doctor's visit to act on — it points toward dietary choices (fermented foods, high-fiber vegetables) that are already well-supported by evidence.

• Interesting, but low urgency. The bulk of